» Articles » PMID: 30655068

Patterns and Risk of Recurrence in Patients with Esophageal Cancer with a Pathologic Complete Response After Chemoradiotherapy Followed by Surgery

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: A pathologic complete response in patients with locally advanced esophageal cancer after chemoradiotherapy and surgery is associated with improved overall and disease-free survival. Nevertheless, approximately one third of patients with a pathologic complete response still have a recurrence. The aim of this study was to evaluate risk factors and patterns of recurrence in patients with locally advanced esophageal cancer who achieved a pathologic complete response after chemoradiotherapy and surgery.

Methods: We performed a retrospective review of a single-institution database of 233 patients with stage II and III esophageal cancer with a pathologic complete response after chemoradiotherapy and surgery between 1997 and 2017. A multivariable competing risk-regression model was used to identify predictors of recurrence.

Results: A total of 61 patients exhibited recurrence in this cohort, 43 with adenocarcinoma and 18 with squamous cell carcinoma. Five-year cumulative incidence of recurrence did not vary by histology. Univariable analysis revealed that poor tumor differentiation (hazard ratio, 2.28; P = .022) and advanced clinical stage (hazard ratio, 1.89; P = .042) are predictors of recurrence in the esophageal adenocarcinoma subgroup, whereas poor tumor differentiation remained the only independent predictor on multivariable analysis in the entire cohort (hazard ratio, 2.28; P = .009). Patients with esophageal adenocarcinoma had a higher incidence of distant recurrences, and patients with esophageal squamous cell carcinoma demonstrated a higher incidence of loco-regional recurrence (P = .039).

Conclusions: Poor tumor differentiation is an independent risk factor for recurrence in patients with esophageal cancer with a pathologic complete response. Although there is no difference in the cumulative incidence of recurrence between esophageal adenocarcinoma and esophageal squamous cell carcinoma, patterns of recurrence appear to differ. Thus, treatment and surveillance strategies may be tailored appropriately.

Citing Articles

Neoadjuvant radiochemotherapy in patients with high-risk locally advanced cervical cancer-results of a clinical series.

Donath S, Schirmer M, Bremmer F, Seif A, Droge L, Guhlich M Strahlenther Onkol. 2025; .

PMID: 39777512 DOI: 10.1007/s00066-024-02340-5.


Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.

Lander E, Aushev V, Huffman B, Hanna D, Dutta P, Ferguson J JCO Precis Oncol. 2024; 8:e2400288.

PMID: 39642325 PMC: 11634147. DOI: 10.1200/PO.24.00288.


Oncologic Outcome of Patients With Pathologic T0 Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.

Chen S, Wang X, Chen Y Cancer Control. 2024; 31:10732748241284905.

PMID: 39259832 PMC: 11406660. DOI: 10.1177/10732748241284905.


Immunotherapy Plus Chemoradiation Improves Overall Survival in Stage IV Esophageal Cancer: A Cohort Study.

Amin S, Lin C Gastro Hep Adv. 2024; 3(3):302-310.

PMID: 39131143 PMC: 11307788. DOI: 10.1016/j.gastha.2023.12.004.


Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery.

Kim J, Yun J, Kim Y, Park S, Lee J, Jung H Ann Surg Oncol. 2024; 31(10):6662-6672.

PMID: 38954089 DOI: 10.1245/s10434-024-15678-y.


References
1.
van Hagen P, Wijnhoven B, Nafteux P, Moons J, Haustermans K, De Hertogh G . Recurrence pattern in patients with a pathologically complete response after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. Br J Surg. 2012; 100(2):267-73. DOI: 10.1002/bjs.8968. View

2.
Kim M, Cho K, Park S, Kim Y, Kim J, Song H . Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009; 75(1):115-21. DOI: 10.1016/j.ijrobp.2008.10.074. View

3.
Rizk N, Seshan V, Bains M, Ilson D, Minsky B, Tang L . Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol. 2007; 2(12):1117-23. DOI: 10.1097/JTO.0b013e31815bfe53. View

4.
Liu B, Bo Y, Wang K, Liu Y, Tang X, Zhao Y . Concurrent neoadjuvant chemoradiotherapy could improve survival outcomes for patients with esophageal cancer: a meta-analysis based on random clinical trials. Oncotarget. 2017; 8(12):20410-20417. PMC: 5386772. DOI: 10.18632/oncotarget.14669. View

5.
. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017; 541(7636):169-175. PMC: 5651175. DOI: 10.1038/nature20805. View